Safety and immunogenicity of a QazCovid-in® inactivated whole-virion vaccine against COVID-19 in healthy adults: A single-centre, randomised, single-blind, placebo-controlled phase 1 and an open-label phase 2 clinical trials with a 6 months follow-up in Kazakhstan
Background: A new inactivated whole-virion QazCovid-in® vaccine against COVID-19 was developed from SARS-CoV-2 isolated in Kazakhstan, inactivated by formaldehyde, and adjuvanted with aluminium hydroxide. Phase 1 and 2 clinical trials aimed at assessing the vaccine's safety, immunogenicity, and...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-09-01
|
| Series: | EClinicalMedicine |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589537021003588 |
| _version_ | 1819137675618156544 |
|---|---|
| author | Kunsulu Zakarya Lespek Kutumbetov Mukhit Orynbayev Yergali Abduraimov Kulyaisan Sultankulova Markhabat Kassenov Gulbanu Sarsenbayeva Ilyas Kulmagambetov Timur Davlyatshin Maria Sergeeva Marina Stukova Berik Khairullin |
| author_facet | Kunsulu Zakarya Lespek Kutumbetov Mukhit Orynbayev Yergali Abduraimov Kulyaisan Sultankulova Markhabat Kassenov Gulbanu Sarsenbayeva Ilyas Kulmagambetov Timur Davlyatshin Maria Sergeeva Marina Stukova Berik Khairullin |
| author_sort | Kunsulu Zakarya |
| collection | DOAJ |
| description | Background: A new inactivated whole-virion QazCovid-in® vaccine against COVID-19 was developed from SARS-CoV-2 isolated in Kazakhstan, inactivated by formaldehyde, and adjuvanted with aluminium hydroxide. Phase 1 and 2 clinical trials aimed at assessing the vaccine's safety, immunogenicity, and the duration of immunity induced by the QazCovid-in® vaccine after one or two immunisations. Methods: From 23.09.2020 to 19.03.2021 we performed a randomised, single-blind, placebo-controlled phase 1 clinical trial and from 18.10.2020 to 17.04.2021 an open-label phase 2 clinical trials of the QazCovid-in® vaccine with a 6 months follow-up at a single centre in Almaty, the Republic of Kazakhstan. Eligible healthy adults aged 18 years and older with no history of laboratory-confirmed SARS-CoV-2 infection were randomly assigned to the treatment groups using a computerised randomisation scheme generator. In the phase 1 clinical trial, two doses of the vaccine (5 μg each) or placebo (0·9% NaCl) were administered intramuscularly to 44 subjects aged 18–50 years, 21 days apart. In the phase 2 trial, 200 healthy participants were randomised into four equal-sized groups according to the age (18–49 or ≥50 years) and either single (day 1) or double (day 1 and 21) vaccination protocol. The primary outcomes were safety and tolerability. The secondary outcome was immunogenicity. The cellular response was measured by a whole-blood cytokine release assay (phase 1 only). The trials were registered with ClinicalTrials.gov NCT04530357. Findings: The QazCovid-in® vaccine was safe and well-tolerated and induced predominantly mild adverse events; no serious or severe adverse events were recorded in both trials. In the phase 1 trial, the percentage of subjects with a fourfold increase of antibody titres (sero conversion) in MNA was 59% after one vaccine dose and amounted to 100% after two doses. Neutralizing antibody titres reached the geometric mean titre (GMT) of 100 after administration of two doses. A statistically significant increase in the levels of pro-inflammatory cytokines after vaccination indicated the Th1-biased response. On day 180, 40% of placebo-treated subjects demonstrated a statistically significant increase in the levels of antibodies measured by both ELISA and MNA, which suggests the infection with SARS-CoV-2. In the phase 2 trial, 100% of subjects aged 18–49 years seroconverted for SARS-CoV-2 on day 21 after the first dose, as indicated by MNA yielding the GMTs of 32 or 30 in the one- and two-dose groups, respectively. Amongst ≥50-year-old subjects, the number of sero conversions in the two- and one-dose groups on day 21 was 94% and 92% with the respective GMTs of 25 and 24. After the second dose, the sero conversion rate reached 100%; however, the GMT was significantly lower when compared with the corresponding value measured in subjects aged 18–49 years (83 vs 143). In both trials, specific antibodies were detected in MNA and ELISA on study day 180, but the titres dropped in comparison to day 42. The results of this study serve as the rationale for the phase 3 study. Interpretation: The QazCovid-in® vaccine is safe and well-tolerated and promotes pronounced humoral immunity which lasts for at least 6 months after double intramuscular immunisation. Funding: The work was funded by the Science Committee of the Ministry of Education and Science of the Republic of Kazakhstan within the framework of the Scientific and Technical Program ''Development of a vaccine against coronavirus infection COVID-1900 . State registration number ?.0927. |
| first_indexed | 2024-12-22T10:54:39Z |
| format | Article |
| id | doaj.art-e6c3add44a0f4793996755ca1d459f79 |
| institution | Directory Open Access Journal |
| issn | 2589-5370 |
| language | English |
| last_indexed | 2024-12-22T10:54:39Z |
| publishDate | 2021-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | EClinicalMedicine |
| spelling | doaj.art-e6c3add44a0f4793996755ca1d459f792022-12-21T18:28:39ZengElsevierEClinicalMedicine2589-53702021-09-0139101078Safety and immunogenicity of a QazCovid-in® inactivated whole-virion vaccine against COVID-19 in healthy adults: A single-centre, randomised, single-blind, placebo-controlled phase 1 and an open-label phase 2 clinical trials with a 6 months follow-up in KazakhstanKunsulu Zakarya0Lespek Kutumbetov1Mukhit Orynbayev2Yergali Abduraimov3Kulyaisan Sultankulova4Markhabat Kassenov5Gulbanu Sarsenbayeva6Ilyas Kulmagambetov7Timur Davlyatshin8Maria Sergeeva9Marina Stukova10Berik Khairullin11Research Institute for Biological Safety Problems of the Science Committee of the Ministry of Education and Science of the Republic of Kazakhstan, Gvardeysk, KazakhstanResearch Institute for Biological Safety Problems of the Science Committee of the Ministry of Education and Science of the Republic of Kazakhstan, Gvardeysk, KazakhstanResearch Institute for Biological Safety Problems of the Science Committee of the Ministry of Education and Science of the Republic of Kazakhstan, Gvardeysk, KazakhstanResearch Institute for Biological Safety Problems of the Science Committee of the Ministry of Education and Science of the Republic of Kazakhstan, Gvardeysk, KazakhstanResearch Institute for Biological Safety Problems of the Science Committee of the Ministry of Education and Science of the Republic of Kazakhstan, Gvardeysk, KazakhstanResearch Institute for Biological Safety Problems of the Science Committee of the Ministry of Education and Science of the Republic of Kazakhstan, Gvardeysk, KazakhstanResearch Institute for Biological Safety Problems of the Science Committee of the Ministry of Education and Science of the Republic of Kazakhstan, Gvardeysk, KazakhstanCentre for Clinical Medicine and Research, Almaty, KazakhstanClinical diagnostic laboratory ‘Omikron 3D’, Almaty, KazakhstanSmorodintsev Research Institute of Influenza, Saint Petersburg, Russian FederationSmorodintsev Research Institute of Influenza, Saint Petersburg, Russian FederationResearch Institute for Biological Safety Problems of the Science Committee of the Ministry of Education and Science of the Republic of Kazakhstan, Gvardeysk, Kazakhstan; Corresponding author.Background: A new inactivated whole-virion QazCovid-in® vaccine against COVID-19 was developed from SARS-CoV-2 isolated in Kazakhstan, inactivated by formaldehyde, and adjuvanted with aluminium hydroxide. Phase 1 and 2 clinical trials aimed at assessing the vaccine's safety, immunogenicity, and the duration of immunity induced by the QazCovid-in® vaccine after one or two immunisations. Methods: From 23.09.2020 to 19.03.2021 we performed a randomised, single-blind, placebo-controlled phase 1 clinical trial and from 18.10.2020 to 17.04.2021 an open-label phase 2 clinical trials of the QazCovid-in® vaccine with a 6 months follow-up at a single centre in Almaty, the Republic of Kazakhstan. Eligible healthy adults aged 18 years and older with no history of laboratory-confirmed SARS-CoV-2 infection were randomly assigned to the treatment groups using a computerised randomisation scheme generator. In the phase 1 clinical trial, two doses of the vaccine (5 μg each) or placebo (0·9% NaCl) were administered intramuscularly to 44 subjects aged 18–50 years, 21 days apart. In the phase 2 trial, 200 healthy participants were randomised into four equal-sized groups according to the age (18–49 or ≥50 years) and either single (day 1) or double (day 1 and 21) vaccination protocol. The primary outcomes were safety and tolerability. The secondary outcome was immunogenicity. The cellular response was measured by a whole-blood cytokine release assay (phase 1 only). The trials were registered with ClinicalTrials.gov NCT04530357. Findings: The QazCovid-in® vaccine was safe and well-tolerated and induced predominantly mild adverse events; no serious or severe adverse events were recorded in both trials. In the phase 1 trial, the percentage of subjects with a fourfold increase of antibody titres (sero conversion) in MNA was 59% after one vaccine dose and amounted to 100% after two doses. Neutralizing antibody titres reached the geometric mean titre (GMT) of 100 after administration of two doses. A statistically significant increase in the levels of pro-inflammatory cytokines after vaccination indicated the Th1-biased response. On day 180, 40% of placebo-treated subjects demonstrated a statistically significant increase in the levels of antibodies measured by both ELISA and MNA, which suggests the infection with SARS-CoV-2. In the phase 2 trial, 100% of subjects aged 18–49 years seroconverted for SARS-CoV-2 on day 21 after the first dose, as indicated by MNA yielding the GMTs of 32 or 30 in the one- and two-dose groups, respectively. Amongst ≥50-year-old subjects, the number of sero conversions in the two- and one-dose groups on day 21 was 94% and 92% with the respective GMTs of 25 and 24. After the second dose, the sero conversion rate reached 100%; however, the GMT was significantly lower when compared with the corresponding value measured in subjects aged 18–49 years (83 vs 143). In both trials, specific antibodies were detected in MNA and ELISA on study day 180, but the titres dropped in comparison to day 42. The results of this study serve as the rationale for the phase 3 study. Interpretation: The QazCovid-in® vaccine is safe and well-tolerated and promotes pronounced humoral immunity which lasts for at least 6 months after double intramuscular immunisation. Funding: The work was funded by the Science Committee of the Ministry of Education and Science of the Republic of Kazakhstan within the framework of the Scientific and Technical Program ''Development of a vaccine against coronavirus infection COVID-1900 . State registration number ?.0927.http://www.sciencedirect.com/science/article/pii/S2589537021003588 |
| spellingShingle | Kunsulu Zakarya Lespek Kutumbetov Mukhit Orynbayev Yergali Abduraimov Kulyaisan Sultankulova Markhabat Kassenov Gulbanu Sarsenbayeva Ilyas Kulmagambetov Timur Davlyatshin Maria Sergeeva Marina Stukova Berik Khairullin Safety and immunogenicity of a QazCovid-in® inactivated whole-virion vaccine against COVID-19 in healthy adults: A single-centre, randomised, single-blind, placebo-controlled phase 1 and an open-label phase 2 clinical trials with a 6 months follow-up in Kazakhstan EClinicalMedicine |
| title | Safety and immunogenicity of a QazCovid-in® inactivated whole-virion vaccine against COVID-19 in healthy adults: A single-centre, randomised, single-blind, placebo-controlled phase 1 and an open-label phase 2 clinical trials with a 6 months follow-up in Kazakhstan |
| title_full | Safety and immunogenicity of a QazCovid-in® inactivated whole-virion vaccine against COVID-19 in healthy adults: A single-centre, randomised, single-blind, placebo-controlled phase 1 and an open-label phase 2 clinical trials with a 6 months follow-up in Kazakhstan |
| title_fullStr | Safety and immunogenicity of a QazCovid-in® inactivated whole-virion vaccine against COVID-19 in healthy adults: A single-centre, randomised, single-blind, placebo-controlled phase 1 and an open-label phase 2 clinical trials with a 6 months follow-up in Kazakhstan |
| title_full_unstemmed | Safety and immunogenicity of a QazCovid-in® inactivated whole-virion vaccine against COVID-19 in healthy adults: A single-centre, randomised, single-blind, placebo-controlled phase 1 and an open-label phase 2 clinical trials with a 6 months follow-up in Kazakhstan |
| title_short | Safety and immunogenicity of a QazCovid-in® inactivated whole-virion vaccine against COVID-19 in healthy adults: A single-centre, randomised, single-blind, placebo-controlled phase 1 and an open-label phase 2 clinical trials with a 6 months follow-up in Kazakhstan |
| title_sort | safety and immunogenicity of a qazcovid in r inactivated whole virion vaccine against covid 19 in healthy adults a single centre randomised single blind placebo controlled phase 1 and an open label phase 2 clinical trials with a 6 months follow up in kazakhstan |
| url | http://www.sciencedirect.com/science/article/pii/S2589537021003588 |
| work_keys_str_mv | AT kunsuluzakarya safetyandimmunogenicityofaqazcovidininactivatedwholevirionvaccineagainstcovid19inhealthyadultsasinglecentrerandomisedsingleblindplacebocontrolledphase1andanopenlabelphase2clinicaltrialswitha6monthsfollowupinkazakhstan AT lespekkutumbetov safetyandimmunogenicityofaqazcovidininactivatedwholevirionvaccineagainstcovid19inhealthyadultsasinglecentrerandomisedsingleblindplacebocontrolledphase1andanopenlabelphase2clinicaltrialswitha6monthsfollowupinkazakhstan AT mukhitorynbayev safetyandimmunogenicityofaqazcovidininactivatedwholevirionvaccineagainstcovid19inhealthyadultsasinglecentrerandomisedsingleblindplacebocontrolledphase1andanopenlabelphase2clinicaltrialswitha6monthsfollowupinkazakhstan AT yergaliabduraimov safetyandimmunogenicityofaqazcovidininactivatedwholevirionvaccineagainstcovid19inhealthyadultsasinglecentrerandomisedsingleblindplacebocontrolledphase1andanopenlabelphase2clinicaltrialswitha6monthsfollowupinkazakhstan AT kulyaisansultankulova safetyandimmunogenicityofaqazcovidininactivatedwholevirionvaccineagainstcovid19inhealthyadultsasinglecentrerandomisedsingleblindplacebocontrolledphase1andanopenlabelphase2clinicaltrialswitha6monthsfollowupinkazakhstan AT markhabatkassenov safetyandimmunogenicityofaqazcovidininactivatedwholevirionvaccineagainstcovid19inhealthyadultsasinglecentrerandomisedsingleblindplacebocontrolledphase1andanopenlabelphase2clinicaltrialswitha6monthsfollowupinkazakhstan AT gulbanusarsenbayeva safetyandimmunogenicityofaqazcovidininactivatedwholevirionvaccineagainstcovid19inhealthyadultsasinglecentrerandomisedsingleblindplacebocontrolledphase1andanopenlabelphase2clinicaltrialswitha6monthsfollowupinkazakhstan AT ilyaskulmagambetov safetyandimmunogenicityofaqazcovidininactivatedwholevirionvaccineagainstcovid19inhealthyadultsasinglecentrerandomisedsingleblindplacebocontrolledphase1andanopenlabelphase2clinicaltrialswitha6monthsfollowupinkazakhstan AT timurdavlyatshin safetyandimmunogenicityofaqazcovidininactivatedwholevirionvaccineagainstcovid19inhealthyadultsasinglecentrerandomisedsingleblindplacebocontrolledphase1andanopenlabelphase2clinicaltrialswitha6monthsfollowupinkazakhstan AT mariasergeeva safetyandimmunogenicityofaqazcovidininactivatedwholevirionvaccineagainstcovid19inhealthyadultsasinglecentrerandomisedsingleblindplacebocontrolledphase1andanopenlabelphase2clinicaltrialswitha6monthsfollowupinkazakhstan AT marinastukova safetyandimmunogenicityofaqazcovidininactivatedwholevirionvaccineagainstcovid19inhealthyadultsasinglecentrerandomisedsingleblindplacebocontrolledphase1andanopenlabelphase2clinicaltrialswitha6monthsfollowupinkazakhstan AT berikkhairullin safetyandimmunogenicityofaqazcovidininactivatedwholevirionvaccineagainstcovid19inhealthyadultsasinglecentrerandomisedsingleblindplacebocontrolledphase1andanopenlabelphase2clinicaltrialswitha6monthsfollowupinkazakhstan |